Clinical Trial Update: A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating CNP520 vs placebo in individuals at risk for onset of Alzheimer's disease was terminated, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CNP520

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimers Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-08-05